QS Investors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

QS Investors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$258K	Hold	3,300	–	–	﹤0.01%	988
2021 Q1	$313K	Hold	3,300	–	–	﹤0.01%	977
2020 Q4	$402K	Buy	3,300 +800	+32%	+$87.6K	﹤0.01%	882
2020 Q3	$219K	Sell	2,500 -10,150	-80%	-$707K	﹤0.01%	1055
2020 Q2	$818K	Hold	12,650	–	–	0.01%	786
2020 Q1	$565K	Hold	12,650	–	–	0.01%	812
2019 Q4	$797K	Hold	12,650	–	–	0.01%	820
2019 Q3	$476K	Hold	12,650	–	–	0.01%	957
2019 Q2	$515K	Buy	+12,650	New	+$451K	0.01%	959

Other funds holding TPTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

QS Investors's TPTX Position: Q2 2021 in Review

QS Investors held its Turning Point Therapeutics, Inc. Common Stock (TPTX) position steady in Q2 2021 at 3,300 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #988.

QS Investors first reported a position in TPTX in Q2 2019 and has held it in 9 quarters since. The position peaked at $818K in Q2 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

QS Investors held 3,300 shares of Turning Point Therapeutics, Inc. Common Stock worth $258K as of Q2 2021.
QS Investors left its Turning Point Therapeutics, Inc. Common Stock share count unchanged in Q2 2021.
Turning Point Therapeutics, Inc. Common Stock made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #988 holding.
QS Investors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 9 quarters since.
QS Investors's Turning Point Therapeutics, Inc. Common Stock position peaked at $818K in Q2 2020.
190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.